Event Review: HDBI Ethics Seminar – Ethics oversight in developmental biology research

The latest instalment of the Human Developmental Biology Initiative (HDBI) Ethics Seminar series tackled the goals and challenges of ethical review for studies involving stem cell-based embryo models (SCBEMs). The seminar offered a short but honest glimpse of where oversight in developmental biology works and where it remains slippery, especially at the edges where research moves faster than rules. While I was reassured that this field has language for its ethical dilemmas, it was still unclear about how that language turns into practice.

Josephine Johnston, a lawyer and bioethicist from the University of Otago in New Zealand, opened the seminar with a talk that traced the historical development of ethics oversight. She outlined how mechanisms have evolved as instruments to support proportionality, independence, and public reassurance around emerging technologies in human reproduction.

Johnston's central message stood out: she acknowledged that even committees can feel 'a bit lost' when faced with vague guidelines. She emphasised that researchers often seek out oversight voluntarily, not merely to tick a box, recognising its value in offering a second perspective and ensuring scrutiny.

For me, understanding how these committees operate in practice would have added value to the discussion. How precisely do committees research unfamiliar techniques, stay impartial, and reach consensus when time is tight and evidence is thin? Johnston flagged classic hard cases such as chimaeras, or the insertion of human cells into non-human animals, but the take-home message remained that 'guidelines are vague' without actionable steps for real-world cases.

That said, her practical advice to the research community listening in – use plain language, avoid inflammatory terminology, and be explicit about what the research does not do – was pragmatic and should be included in the methods section of every paper.

The second speaker was Jeremy Sugarman, a physician and professor of bioethics and medicine at John Hopkins University in Baltimore, Maryland. Professor Sugarman examined the ethical concerns around human SCBEMs, including questions of moral status, provenance, and safety. He separated legal permissibility from ethical acceptability and stressed the need for rigorous ethical justification for engaging in such research. His three justifications for these studies – scientific value, social value, and the potential to reduce reliance on human embryos and fetal tissue – provide a defensible baseline.

Professor Sugarman also delved into the complexities of moral status, highlighting the problem that as SCBEMs acquire functional features of embryos – without being embryos by origin or morphology – our current guidelines start to creak. Ultimately, his discussion of the provenance of biological materials – whether donors gave informed consent, and whether current uses align with that consent (referencing real-world examples such as the HeLa cell line controversy) – underscored the need for transparency and accountability over downstream use.

Both speakers converged on the 14-day rule as a policy tool, rather than a moral boundary, and highlighted its limitations as new SCBEMs mature differently from embryos. Johnston advocated for renewed public engagement and clearer communication about the purpose and limits of such studies. If the public believes '14 days' is the moral line, we need to explain why we are moving from a time limit to tests based on what the SCBEMs can do, and what safeguards will replace that old rule.

Overall, I was left wanting more insight into the grey zones. If a SCBEM cannot implant, yet recapitulates the first steps in organising a nervous system, is that ethically lighter because reproduction is impossible or ethically heavier because morally significant functions are starting to emerge? Professor Sugarman acknowledged that there is no single framework for every case, and proceeded to examine the use of principles such as proportionality and subsidiarity (borrowed from EU policy) to guide ethical decisionmaking.

In this context, 'proportionality' means (among other things) that scrutiny should scale with risk. Meanwhile, 'subsidiarity' is often taken to mean that ethics decisions should be made at the lowest competent level, and should only escalate when the issue exceeds that level's expertise (although Professor Sugarman has argued that the true meaning of the term 'subsidiarity' is distorted by some of its current uses). To avoid ad hoc thresholds, concrete functional criteria – for example, specified signs of gastrulation-like organisation – could be established that automatically require independent review, plus a post-study ethics audit, before researchers scale the work or share protocols with others.

Both Johnston and Professor Sugarman highlighted the need for interdisciplinary dialogue between ethicists and researchers, the value of working groups to tackle emerging questions, and clearer, more accessible communication. As Johnston noted, the language used to describe research can shape public perception and influence policy debates. Researchers must be mindful of how they present their work, especially since the ethical questions raised by SCBEMs and related technologies are not only scientifically complex, but also socially consequential. Addressing these questions requires not just policy and procedure, but also a commitment to ongoing dialogue, critical reflection, and shared responsibility.

Overall, while the speakers provided conceptual clarity, I would have welcomed one or two detailed case studies showing the reality of the process of ethical review and how researchers in the field can learn from previous failures – for example, a committee deadlocked on a chimeric brain-organoid study, or a project spanning jurisdictions that forced a protocol rewrite. The audience may have found the pace brisk, yet the two talks complemented each other and made it worth our time, especially for those of us tracking how policy around SCBEMs is evolving.